Abstract
The antitumor activity of cis-diamminedichloroplatinum(II) (cP) and human recombinant interleukin-1α (IL-1α) was studied in RIF-1 and SC VII solid tumor models and in a cP-resistant subline of RIF-1 designated RIF-R1cP. In RIF-1 tumors, clonogenic cell survival after cP plus IL-1α combinations was highly schedule and IL-1α dose dependent. More than additive clonogenic cell kill was seen when cP was given 6 h before, but not 8 h before or at 2-6 h after IL-1α. Time course studies indicated that maximal clonogenic cell killing was achieved within 4-6 h after the cP plus IL-1α combination, with little or no recovery for up to 24 h. In vivo dose-response studies indicated that cP plus IL-1α combinations induced more clonogenic cell kill than cP alone in all three tumor models, and analysis by the median effect principle indicated highly synergistic antitumor activity. Dexamethasone but not indomethacin inhibited the synergistic interaction. IL-1α had no effect on the cytotoxicity of cP in SCC VII cells in vitro, and neither in vitro hypoxia nor in vivo ischemia, induced by clamping tumor blood supply, significantly affected cP clonogenic cell killing. Increased clonogenic cell killing was seen, however, after removal of the clamp, implicating reperfusion events, such as oxyradical stress, as a potential mechanism for increased cP cytotoxicity in SCC VII solid tumors. The data from our model systems provide a rationale for additional work to define the mechanisms of the synergistic antitumor activity of the cP plus IL-1α combination and indicate that IL-1α might be a useful adjunct to increase the clinical efficacy of cP-containing strategies for both sensitive and cP-resistant cancers.
| Original language | English |
|---|---|
| Pages (from-to) | 1091-1097 |
| Number of pages | 7 |
| Journal | Cancer Research |
| Volume | 53 |
| Issue number | 5 |
| State | Published - Mar 1 1993 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tomors. / Braunschweiger, Paul G; Basrur, Vathsala S.; Santos, Octavio; Markoe, Arnold; Houdek, Pavel V.; Schwade, James G.
In: Cancer Research, Vol. 53, No. 5, 01.03.1993, p. 1091-1097.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tomors
AU - Braunschweiger, Paul G
AU - Basrur, Vathsala S.
AU - Santos, Octavio
AU - Markoe, Arnold
AU - Houdek, Pavel V.
AU - Schwade, James G.
PY - 1993/3/1
Y1 - 1993/3/1
N2 - The antitumor activity of cis-diamminedichloroplatinum(II) (cP) and human recombinant interleukin-1α (IL-1α) was studied in RIF-1 and SC VII solid tumor models and in a cP-resistant subline of RIF-1 designated RIF-R1cP. In RIF-1 tumors, clonogenic cell survival after cP plus IL-1α combinations was highly schedule and IL-1α dose dependent. More than additive clonogenic cell kill was seen when cP was given 6 h before, but not 8 h before or at 2-6 h after IL-1α. Time course studies indicated that maximal clonogenic cell killing was achieved within 4-6 h after the cP plus IL-1α combination, with little or no recovery for up to 24 h. In vivo dose-response studies indicated that cP plus IL-1α combinations induced more clonogenic cell kill than cP alone in all three tumor models, and analysis by the median effect principle indicated highly synergistic antitumor activity. Dexamethasone but not indomethacin inhibited the synergistic interaction. IL-1α had no effect on the cytotoxicity of cP in SCC VII cells in vitro, and neither in vitro hypoxia nor in vivo ischemia, induced by clamping tumor blood supply, significantly affected cP clonogenic cell killing. Increased clonogenic cell killing was seen, however, after removal of the clamp, implicating reperfusion events, such as oxyradical stress, as a potential mechanism for increased cP cytotoxicity in SCC VII solid tumors. The data from our model systems provide a rationale for additional work to define the mechanisms of the synergistic antitumor activity of the cP plus IL-1α combination and indicate that IL-1α might be a useful adjunct to increase the clinical efficacy of cP-containing strategies for both sensitive and cP-resistant cancers.
AB - The antitumor activity of cis-diamminedichloroplatinum(II) (cP) and human recombinant interleukin-1α (IL-1α) was studied in RIF-1 and SC VII solid tumor models and in a cP-resistant subline of RIF-1 designated RIF-R1cP. In RIF-1 tumors, clonogenic cell survival after cP plus IL-1α combinations was highly schedule and IL-1α dose dependent. More than additive clonogenic cell kill was seen when cP was given 6 h before, but not 8 h before or at 2-6 h after IL-1α. Time course studies indicated that maximal clonogenic cell killing was achieved within 4-6 h after the cP plus IL-1α combination, with little or no recovery for up to 24 h. In vivo dose-response studies indicated that cP plus IL-1α combinations induced more clonogenic cell kill than cP alone in all three tumor models, and analysis by the median effect principle indicated highly synergistic antitumor activity. Dexamethasone but not indomethacin inhibited the synergistic interaction. IL-1α had no effect on the cytotoxicity of cP in SCC VII cells in vitro, and neither in vitro hypoxia nor in vivo ischemia, induced by clamping tumor blood supply, significantly affected cP clonogenic cell killing. Increased clonogenic cell killing was seen, however, after removal of the clamp, implicating reperfusion events, such as oxyradical stress, as a potential mechanism for increased cP cytotoxicity in SCC VII solid tumors. The data from our model systems provide a rationale for additional work to define the mechanisms of the synergistic antitumor activity of the cP plus IL-1α combination and indicate that IL-1α might be a useful adjunct to increase the clinical efficacy of cP-containing strategies for both sensitive and cP-resistant cancers.
UR - http://www.scopus.com/inward/record.url?scp=0027450891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027450891&partnerID=8YFLogxK
M3 - Article
VL - 53
SP - 1091
EP - 1097
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0099-7013
IS - 5
ER -